Get the Stockscreener App
65.56
3.26%
2.07
After Hours:
65.15
-0.41
-0.63%
Veradermics Inc stock is traded at $65.56, with a volume of 455.84K.
It is up +3.26% in the last 24 hours and up +55.47% over the past month.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
See More
Previous Close:
$63.49
Open:
$63.65
24h Volume:
455.84K
Relative Volume:
1.92
Market Cap:
$2.30B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.10%
1M Performance:
+55.47%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$62.28
$66.54
1-Week Range:
$55.00
$66.54
52-Week Range:
$32.00
$66.54
Veradermics Inc Stock (MANE) Company Profile
Compare MANE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
65.56 | 2.23B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | Citigroup | Buy |
| Mar-02-26 | Initiated | Jefferies | Buy |
| Mar-02-26 | Initiated | Leerink Partners | Outperform |
Veradermics Inc Stock (MANE) Latest News
Veradermics, Incorporated(NYSE: MANE) added to S&P TMI Index - marketscreener.com
Veradermics to present hair loss treatment data at AAD meeting By Investing.com - Investing.com South Africa
Veradermics Announces Presentations on VDPHL01 and Patient Experi - The National Law Review
Veradermics to present hair loss treatment data at AAD meeting - Investing.com
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting - Business Wire
Veradermics Inc (MANE) Financial Ratios - Investing.com India
Veradermics (MANE) Stock Analysis Report | Financials & Insights - Benzinga Japan
Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal? - Yahoo Finance
MANE Should I Buy - Intellectia AI
A Look At Veradermics (MANE) Valuation After Recent Share Price Momentum And DCF Upside Signals - simplywall.st
Dermatology drug maker Veradermics set for Miami investor spotlight - Stock Titan
Veradermics to Participate in Upcoming March Investor Conferences - Business Wire
Veradermics, Incorporated: Revenue and Earnings Analysts Forecasts Revisions | MANE | US9229671048 - marketscreener.com
MANE Technical Analysis & ETF Price Forecast - Intellectia AI
Veradermics, Incorporated: Dividend historical data and projections - marketscreener.com
Leerink initiates Veradermics stock with Outperform rating By Investing.com - Investing.com UK
Cantor Fitzgerald Initiates VeraDermics at Overweight - marketscreener.com
Jefferies Initiates VeraDermics at Buy With $75 Price Target - marketscreener.com
Citigroup Initiates VeraDermics at Buy With $85 Price Target - marketscreener.com
Leerink Initiates VeraDermics at Outperform With $75 Price Target - marketscreener.com
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill - Proactive financial news
Leerink initiates Veradermics stock with Outperform rating - Investing.com South Africa
Jefferies initiates Veradermics stock with buy rating on phase 3 prospects - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating - Investing.com
Veradermics initiated with a Buy at Jefferies - TipRanks
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell – Company Announcement - Financial Times
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell - Finviz
Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue Losses - Yahoo Finance
Veradermics completes enrollment in second pivotal phase 3 clinical trial of Vdphl01 for male pattern hair loss - marketscreener.com
Veradermics Completes Enrollment in 2nd Phase 3 Study of VDPHL01 for Male Pattern Hair Loss - marketscreener.com
Veradermics completes enrollment in phase 3 trials for hair loss drug - Investing.com Canada
Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss - Intellectia AI
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss - Business Wire
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all - statnews.com
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - BioSpace
Veradermics completes $294.8 million IPO with full underwriter option exercise - Investing.com
Veradermics CEO has a great hair day with 122% pop in IPO - Endpoints News
Hair regrowth biotech raises $256m in ‘upsized’ IPO - longevity.technology
Veradermics’ IPO raises $256M in stellar NYSE debut - Hartford Business Journal
Veradermics Raises $256 Million in Upsized Initial Public Offering - Pharmaceutical Executive
A cut above: Veradermics locks in $256M IPO and shares spike - Fierce Pharma
MANE Forecast — Price Prediction for 2026. Should I Buy MANE? - Intellectia AI
Veradermics announces pricing of upsized IPO - The Pharma Letter
Eikon, Veradermics close IPOs, as Salspera joins queue - pharmaphorum
Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO - Law360
Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO - Smartkarma
Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss - MedCity News
Veradermics prices upsized IPO at $17 per share, raises $256.3 million - Investing.com Nigeria
Veradermics Inc Stock (MANE) Financials Data
There is no financial data for Veradermics Inc (MANE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):